PBX1 and acute lymphoblastic leukemia: Remarkably, the novel specific enzymatic MTOR inhibitor torin-1 was the most potent compound in a small-scale drug screen using several small molecule inhibitors in E2A-PBX1+/preBCR+ ALL cells, validating the shRNA screen data using an independent pharmacologic approach (Fig. 1C).